Free Trial

Barclays (BCS) 10K Form and Latest SEC Filings 2026

Barclays logo
$22.85 -0.30 (-1.28%)
Closing price 11/12/2026 03:59 PM Eastern
Extended Trading
$22.97 +0.12 (+0.51%)
As of 11/12/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Barclays SEC Filings & Recent Activity

Barclays (NYSE:BCS) has submitted 1,083+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Barclays's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on November 6, 2026.

20-F
Barclays Files Annual Report on Feb. 10, 2026

The 20-F contains Barclays's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Barclays SEC Filing History

Browse Barclays' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/06/2026 2:44 PM
Barclays (312069) Filed by
Cartesian Therapeutics, Inc. (1453687) Subject
Form SCHEDULE 13G/A
11/06/2026 2:45 PM
Barclays (312069) Filed by
Crown Reserve Acquisition Corp. I (2070887) Subject
Crown Reserve Acquisition Corp. I (2070887) Subject
Crown Reserve Acquisition Corp. I (2070887) Subject
Crown Reserve Acquisition Corp. I (2070887) Subject
Form SCHEDULE 13G/A
11/06/2026 2:30 PM
Barclays (312069) Filed by
Calisa Acquisition Corp (2026767) Subject
Calisa Acquisition Corp (2026767) Subject
Calisa Acquisition Corp (2026767) Subject
Form SCHEDULE 13G/A
11/06/2026 2:32 PM
Barclays (312069) Filed by
Commerce.com, Inc. (1626450) Subject
Commerce.com, Inc. (1626450) Subject
Form SCHEDULE 13G/A
11/06/2026 2:34 PM
Barclays (312069) Filed by
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
Form SCHEDULE 13G/A
11/06/2026 2:36 PM
Barclays (312069) Filed by
Penumbra Inc (1321732) Subject
Form SCHEDULE 13G/A
11/06/2026 2:37 PM
Barclays (312069) Filed by
MERCER INTERNATIONAL INC. (1333274) Subject
Form SCHEDULE 13G/A
11/06/2026 2:38 PM
Barclays (312069) Filed by
JELD-WEN Holding, Inc. (1674335) Subject
Form SCHEDULE 13G/A
11/06/2026 2:14 PM
Barclays (312069) Filed by
Cannae Holdings, Inc. (1704720) Subject
Form SCHEDULE 13G
11/06/2026 2:16 PM
Barclays (312069) Filed by
Bluerock Acquisition Corp. II (2098410) Subject
Form SCHEDULE 13G
11/06/2026 2:23 PM
Barclays (312069) Filed by
Cable One, Inc. (1632127) Subject
Form SCHEDULE 13G
11/06/2026 2:24 PM
Barclays (312069) Filed by
FORWARD AIR CORP (912728) Subject
Form SCHEDULE 13G/A
11/06/2026 2:26 PM
Barclays (312069) Filed by
SilverBox Corp IV (2015947) Subject
Form SCHEDULE 13G/A
11/06/2026 1:44 PM
Barclays (312069) Filed by
SHENANDOAH TELECOMMUNICATIONS CO/VA/ (354963) Subject
Form SCHEDULE 13G
11/06/2026 1:49 PM
Barclays (312069) Filed by
Enviri Corp (2104052) Subject
Form SCHEDULE 13G
11/06/2026 1:52 PM
Barclays (312069) Filed by
QUANTUM CORP /DE/ (709283) Subject
Form SCHEDULE 13G
11/06/2026 1:54 PM
Barclays (312069) Filed by
Digital Asset Acquisition Corp. (2052162) Subject
Digital Asset Acquisition Corp. (2052162) Subject
Digital Asset Acquisition Corp. (2052162) Subject
Form SCHEDULE 13G
11/06/2026 1:55 PM
Barclays (312069) Filed by
Biglari Holdings Inc. (1726173) Subject
Biglari Holdings Inc. (1726173) Subject
Form SCHEDULE 13G
11/06/2026 1:29 PM
Barclays (312069) Filed by
New Fortress Energy Inc. (1749723) Subject
Form SCHEDULE 13G
11/06/2026 1:38 PM
Aldeyra Therapeutics, Inc. (1341235) Subject
Barclays (312069) Filed by
Form SCHEDULE 13G
11/06/2026 1:15 PM
Barclays (312069) Filed by
BOX INC (1372612) Subject
Form SCHEDULE 13G
11/06/2026 1:18 PM
Barclays (312069) Filed by
Live Oak Acquisition Corp. VI (2115191) Subject
Form SCHEDULE 13G
11/06/2026 1:19 PM
Barclays (312069) Filed by
Weave Communications, Inc. (1609151) Subject
Form SCHEDULE 13G
11/06/2026 1:23 PM
Barclays (312069) Filed by
Haymaker Acquisition Corp V (2111838) Subject
Form SCHEDULE 13G
11/06/2026 1:25 PM
Barclays (312069) Filed by
Pinnacle Acquisition Corp (2123955) Subject
Pinnacle Acquisition Corp (2123955) Subject
Form SCHEDULE 13G
11/06/2026 7:43 AM
Barclays (312069) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
11/05/2026 3:22 PM
Barclays (312069) Filer
Form 8-A12B
11/05/2026 1:57 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/04/2026 11:57 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
11/03/2026 11:40 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2026 7:59 AM
Barclays (312069) Subject
Form FWP
11/02/2026 1:42 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/02/2026 1:06 PM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
11/02/2026 5:47 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/02/2026 5:06 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
10/30/2026 7:02 AM
Barclays (312069) Subject
Form FWP
10/30/2026 6:50 AM
Barclays (312069) Subject
Form FWP
10/30/2026 6:56 AM
Barclays (312069) Subject
Form FWP
10/29/2026 8:36 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
10/23/2026 6:03 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2026 11:45 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
My public warning after 55 years of watching the markets (Ad)

Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel

See Martin Weiss's full warning before this risk spreads further
10/22/2026 5:14 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/09/2026 5:30 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2026 3:50 PM
Barclays (312069) Subject
Cardoso da silva Sergio Tony (2157144) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/01/2026 5:01 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/24/2026 2:23 PM
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/24/2026 11:12 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2026 11:45 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/14/2026 12:29 PM
Barclays (312069) Subject
NEW YORK STOCK EXCHANGE LLC (876661) Filed by
Form 25-NSE
09/11/2026 11:01 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 11:38 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/08/2026 12:55 PM
Barclays (312069) Filed by
QVC Group, Inc. (1254699) Subject
Form SCHEDULE 13G
09/08/2026 1:01 PM
Barclays (312069) Filed by
QVC Group, Inc. (1254699) Subject
Form SCHEDULE 13G/A
09/08/2026 12:15 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2026 10:00 AM
Barclays (312069) Filer
Form N-PX
Annual Report of Proxy Voting Record of Registered Management Investment Company  
09/03/2026 2:24 PM
Barclays (312069) Reporting
QVC Group, Inc. (1254699) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/01/2026 10:04 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2026 11:31 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2026 4:40 PM
Barclays (312069) Filed by
Rising Dragon Acquisition Corp. (2018145) Subject
Form SCHEDULE 13G/A
08/13/2026 6:38 PM
Barclays (312069) Filed by
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
Form SCHEDULE 13G/A
08/13/2026 6:24 PM
Barclays (312069) Filed by
Range Capital Acquisition Corp. (2035644) Subject
Range Capital Acquisition Corp. (2035644) Subject
Form SCHEDULE 13G/A
08/13/2026 6:24 PM
Barclays (312069) Filed by
Tavia Acquisition Corp. (2020385) Subject
Tavia Acquisition Corp. (2020385) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
BEL FUSE INC /NJ (729580) Subject
BEL FUSE INC /NJ (729580) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
EVERSPIN TECHNOLOGIES INC. (1438423) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
Zentalis Pharmaceuticals, Inc. (1725160) Subject
Form SCHEDULE 13G/A
08/13/2026 6:12 PM
Barclays (312069) Filed by
NewHold Investment Corp. III (2043699) Subject
Form SCHEDULE 13G/A
08/13/2026 6:12 PM
Barclays (312069) Filed by
Madison Square Garden Entertainment Corp. (1952073) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Launch Two Acquisition Corp. (2023676) Subject
Launch Two Acquisition Corp. (2023676) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Roman DBDR Acquisition Corp. II (2032528) Subject
Form SCHEDULE 13G
08/13/2026 5:47 PM
Barclays (312069) Filed by
Penumbra Inc (1321732) Subject
Form SCHEDULE 13G
08/13/2026 5:47 PM
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Barclays (312069) Filed by
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Cartesian Therapeutics, Inc. (1453687) Subject
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Liberty Broadband Corp (1611983) Subject
Liberty Broadband Corp (1611983) Subject
Liberty Broadband Corp (1611983) Subject
Form SCHEDULE 13G/A
08/13/2026 5:34 PM
Barclays (312069) Filed by
CH4 Natural Solutions Corp (2044817) Subject
CH4 Natural Solutions Corp (2044817) Subject
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Oaktree Acquisition Corp. III Life Sciences (2029769) Subject
Oaktree Acquisition Corp. III Life Sciences (2029769) Subject
Form SCHEDULE 13G
08/13/2026 5:21 PM
Barclays (312069) Filed by
ProCap Acquisition Corp (2056634) Subject
Form SCHEDULE 13G
08/13/2026 5:22 PM
Barclays (312069) Filed by
FORWARD AIR CORP (912728) Subject
Form SCHEDULE 13G
08/13/2026 5:22 PM
Barclays (312069) Filed by
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
Form SCHEDULE 13G
08/10/2026 10:53 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/07/2026 11:45 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/06/2026 10:51 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 12:05 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 6:27 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2026 12:38 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2026 9:08 AM
Barclays (312069) Filer
Form CERT
07/01/2026 6:54 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2026 1:20 PM
Barclays (312069) Filer
Form 8-A12B
06/26/2026 11:57 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2026 6:14 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 11:32 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
My next big call (under $1) (Ad)

17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel

06/22/2026 11:38 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
06/22/2026 5:12 AM
Barclays (312069) Subject
Form FWP
06/22/2026 5:18 AM
Barclays (312069) Subject
Form FWP
06/22/2026 5:06 AM
Barclays (312069) Subject
Form FWP
06/18/2026 6:58 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
06/16/2026 11:23 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2026 12:59 PM
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 5:01 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 12:24 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Barclays SEC Filings - Frequently Asked Questions

Barclays (BCS) has submitted 1,083+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Barclays's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Barclays's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on November 6, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NYSE:BCS are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/6/2026. New filings are added as they're published.
From Our Partners